CRUKD/21/005 CURATE A CRUK first in human Phase I/II trial of TT702, a selective adenosine A2BR agonist, given orally as a monotherapy & in combination in advanced cancer including prostate cancer (mCRPC)
We use cookies to keep your session secure, remember your preferences, and analyse site traffic with Google Analytics.
By continuing to use GrantFunds you agree to our
Privacy Policy
and
Terms of Use.